Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
| Therapy Name | Gemcitabine |
| Synonyms | |
| Therapy Description |
Gemzar (gemcitabine) is converted in cells to difluorodeoxycytidine di- and triphosphate (dFdCDP, dFdCTP), which act to inhibit ribonucleoside reductase and as a deoxynucleotide analog respectively, resulting in DNA strand termination and apoptosis (NCI Drug Dictionary). |
Filtering
- Case insensitive filtering will display rows where any text in any cell matches the filter term
- Simple literal full or partial string matches
- Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
- Use quotes to match a longer phrase which contains spaces "mtor c1483f"
Sorting
- Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Gemcitabine | Gemzar | Difluorodeoxycytidine Hydrochlorothiazide|LY-188011 | Chemotherapy - Antimetabolite 14 | Gemzar (gemcitabine) is converted in cells to difluorodeoxycytidine di- and triphosphate (dFdCDP, dFdCTP), which act to inhibit ribonucleoside reductase and as a deoxynucleotide analog respectively, resulting in DNA strand termination and apoptosis (NCI Drug Dictionary). |
Filtering
- Case insensitive filtering will display rows where any text in any cell matches the filter term
- Simple literal full or partial string matches
- Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
- Use quotes to match a longer phrase which contains spaces "mtor c1483f"
Sorting
- Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
Filtering
- Case insensitive filtering will display rows where any text in any cell matches the filter term
- Simple literal full or partial string matches
- Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
- Use quotes to match a longer phrase which contains spaces "mtor c1483f"
Sorting
- Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT02399137 | Phase II | Nab-paclitaxel Gemcitabine MM-141 | A Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer | Completed | USA | ESP | DEU | CAN | 2 |
| NCT01532687 | Phase II | Gemcitabine Gemcitabine + Pazopanib | Gemcitabine Hydrochloride With or Without Pazopanib Hydrochloride in Treating Patients With Refractory Soft Tissue Sarcoma | Completed | USA | 0 |
| NCT02138383 | Phase I | Enzalutamide Nab-paclitaxel Gemcitabine | Enzalutamide in Combination With Gemcitabine and Nab-Paclitaxel for the Treatment of Advanced Pancreatic Cancer | Completed | USA | 0 |
| NCT02079636 | Phase I | LY3023414 Abemaciclib Gemcitabine Pemetrexed Disodium Ramucirumab | A Study of LY2835219 in Combination With Another Anti-cancer Drug in Participants With Lung Cancer (NSCLC) | Completed | USA | ESP | 0 |
| NCT03432741 | Phase I | Carfilzomib Daratumumab Obinutuzumab Gemcitabine Trastuzumab Romidepsin Nivolumab Rituximab Belinostat Pembrolizumab | Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer | Recruiting | USA | 0 |
| NCT02309177 | Phase I | Carboplatin Gemcitabine Nab-paclitaxel + Nivolumab | Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast Cancer | Completed | USA | 0 |
| NCT01497392 | Phase I | Gemcitabine Dovitinib Capecitabine | Dovitinib Lactate, Gemcitabine Hydrochloride, and Capecitabine in Treating Patients With Advanced or Metastatic Solid Tumors, Pancreatic Cancer and Biliary Cancers | Completed | USA | 0 |
| NCT00936936 | Phase II | Gemcitabine Ifosfamide Etoposide Melphalan Etoposide + Ifosfamide Docetaxel + Gemcitabine + Melphalan Bevacizumab + Carboplatin | High-dose Chemotherapy for Poor-prognosis Relapsed Germ-Cell Tumors | Active, not recruiting | USA | 0 |
| NCT04383119 | Phase II | Gemcitabine Trabectedin | Trial in Patients With Metastatic or Locally Advanced Leiomyosarcoma (ISG-ARTICLE) | Active, not recruiting | ITA | 0 |
| NCT02621151 | Phase II | Pembrolizumab Gemcitabine | Pembrolizumab (MK3475), Gemcitabine, and Concurrent Hypofractionated Radiation Therapy for Muscle-Invasive Urothelial Cancer of the Bladder | Active, not recruiting | USA | 0 |
| NCT02117024 | Phase II | Cyclophosphamide + HS-110 Pemetrexed Disodium Vinorelbine Erlotinib Gemcitabine Docetaxel Paclitaxel | A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer | Terminated | USA | 0 |
| NCT02409355 | Phase III | Carboplatin Cisplatin Gemcitabine Atezolizumab | A Study of MPDL3280A Compared With Gemcitabine + Cisplatin or Carboplatin in Patients With Stage IV Squamous Non-Small Cell Lung Cancer | Terminated | USA | ITA | FRA | ESP | DEU | 9 |
| NCT03734029 | Phase III | Trastuzumab deruxtecan Nab-paclitaxel Capecitabine Paclitaxel Gemcitabine Eribulin | Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04] | Active, not recruiting | USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT | 12 |
| NCT02595892 | Phase II | Berzosertib Gemcitabine | Gemcitabine Hydrochloride Alone or With VX-970 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | Active, not recruiting | USA | 0 |
| NCT02574078 | Phase Ib/II | Crizotinib + Nivolumab Erlotinib + Nivolumab Nivolumab + Pemetrexed Disodium Bevacizumab Carboplatin + Pemetrexed Disodium Bevacizumab + Nivolumab Nivolumab Erlotinib Carboplatin + Paclitaxel Carboplatin + Docetaxel Carboplatin + Nab-paclitaxel Carboplatin + Gemcitabine Paclitaxel Docetaxel Pemetrexed Disodium Gemcitabine | A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC) (CheckMate370) | Completed | USA | 0 |
| NCT02275039 | Phase I | MVAp53 Gemcitabine | p53MVA Vaccine and Gemcitabine Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer | Completed | USA | 0 |
| NCT02237157 | Phase I | Gemcitabine | A Dose Escalation Safety Study of Locally-Delivered Gemcitabine in Pancreatic Cancer | Completed | USA | 0 |
| NCT03088059 | Phase II | Niraparib Durvalumab + Monalizumab Methotrexate Carboplatin Rogaratinib Mitomycin C Docetaxel Afatinib Paclitaxel Durvalumab Monalizumab Palbociclib Bleomycin Gemcitabine Fluorouracil | Biomarker-based Study in R/M SCCHN (UPSTREAM) | Recruiting | ITA | FRA | BEL | 1 |
| NCT03770299 | Phase II | Docetaxel Nivolumab Paclitaxel Cisplatin Carboplatin Gemcitabine Pemetrexed Disodium Vinorelbine | An Investigational Immuno-therapy Study of Nivolumab Given After Surgery in Non-Small Cell Lung Cancer (NSCLC) Participants With Minimal Residual Disease (CheckMate 9TN) | Withdrawn | 0 | |
| NCT02620423 | Phase I | Gemcitabine Fluorouracil Irinotecan Pelareorep Leucovorin Pembrolizumab | Study of Pembrolizumab With REOLYSIN and Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma | Completed | USA | 0 |
| NCT02194829 | Phase Ib/II | Paclitaxel Gemcitabine Adavosertib | Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Previously Untreated Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery | Active, not recruiting | USA | 0 |
| NCT03923842 | Phase II | Gemcitabine Denosumab + Gemcitabine | Denosumab In Ebv Nasopharyngeal Carcinoma As A Model For RankMediated Immunologic Modulation Of Virus-Related Tumours (Dern) | Recruiting | ITA | 0 |
| NCT01647828 | Phase Ib/II | Nab-paclitaxel Gemcitabine Tarextumab | A Phase 1b/2 Study of OMP-59R5 in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Stage IV Pancreatic Cancer | Completed | USA | 0 |
| NCT01908478 | Phase I | Veliparib Gemcitabine | A Phase I Study of Veliparib (ABT-888) in Combination With Gemcitabine and Intensity Modulated Radiation Therapy in Patients With Locally Advanced, Unresectable Pancreatic Cancer | Completed | USA | 0 |
| NCT03607643 | Phase Ib/II | Temozolomide Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Bevacizumab + Cannabidiol + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Bortezomib Bortezomib + Cannabidiol Cannabidiol + Gemcitabine Cannabidiol + Temozolomide Gemcitabine | A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies | Unknown status | USA | 0 |
| NCT01506973 | Phase Ib/II | Hydroxychloroquine Gemcitabine | A Phase I/II/Pharmacodynamic Study of Hydroxychloroquine in Combination With Gemcitabine/Abraxane to Inhibit Autophagy in Pancreatic Cancer | Completed | USA | 0 |
| NCT02282020 | Phase III | Topotecan Paclitaxel Pegylated liposomal-doxorubicin Gemcitabine Olaparib | Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments (SOLO3) | Completed | USA | ITA | ESP | CAN | BEL | 8 |
| NCT04711824 | Phase Ib/II | Nab-paclitaxel Cisplatin Durvalumab + Olaparib Paclitaxel Capecitabine Gemcitabine Carboplatin Eribulin | Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases | Recruiting | USA | 0 |
| NCT03563144 | Phase II | Gemcitabine Gemcitabine + Nab-paclitaxel Aldoxorubicin + ALT-803 + Avelumab + Bevacizumab + Capecitabine + Cyclophosphamide + ETBX-011 + ETBX-021 + ETBX-051 + ETBX-061 + Fluorouracil + Gemcitabine + GI-4000 + GI-6207 + GI-6301 + haNK cells + Leucovorin + Nab-paclitaxel + Oxaliplatin | QUILT-3.088: NANT Pancreatic Cancer Vaccine | Withdrawn | USA | 0 |
| NCT02589145 | Phase Ib/II | Lenalidomide Pyridoxine Dexamethasone Busulfan + Melphalan Enoxaparin Rituximab Gemcitabine Vorinostat Palifermin | Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype | Terminated | USA | 0 |
| NCT02551718 | Phase I | Bosutinib Irinotecan Romidepsin Busulfan Melphalan Nilotinib Crizotinib Cytarabine Mitoxantrone Dasatinib Pazopanib Paclitaxel Clofarabine Hydroxyurea Tretinoin Carfilzomib Nelarabine Bexarotene Pentostatin Everolimus Cabozantinib Mercaptopurine Methotrexate Cladribine Thioguanine Daunorubicin Ponatinib Etoposide Afatinib Gefitinib Gemcitabine Regorafenib Arsenic trioxide Trametinib Imatinib Erlotinib Dabrafenib Decitabine Axitinib Azacitidine Ruxolitinib Fludarabine Lapatinib Ceritinib Sirolimus Sorafenib Lomustine Sunitinib Cabazitaxel Temsirolimus Topotecan Bortezomib Pralatrexate | High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia | Completed | USA | 0 |
| NCT03137771 | Phase II | Docetaxel Pemetrexed Disodium Gemcitabine Erlotinib | Maintenance Chemotherapy With or Without Stereotactic Body Radiation Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer | Suspended | USA | CAN | 2 |
| NCT04747236 | Phase II | Pralatrexate Belinostat Azacitidine + Romidepsin Gemcitabine Romidepsin | A Randomized, Phase IIB, Multicenter, Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in Patients With Relapse or Refractory Peripheral T-cell Lymphoma (PTCL) | Recruiting | USA | 0 |
| NCT02576574 | Phase III | Gemcitabine Paclitaxel Cisplatin Avelumab Pemetrexed Disodium Carboplatin | Avelumab in First-line Non-Small Cell Lung Cancer (JAVELIN Lung 100) | Active, not recruiting | USA | ITA | FRA | ESP | DEU | CAN | BEL | 35 |
| NCT02265510 | Phase I | Gemcitabine Carfilzomib Dexamethasone Lenalidomide Nab-paclitaxel Azacitidine INCB052793 Bortezomib | An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies | Terminated | USA | 0 |
| NCT02365766 | Phase Ib/II | Cisplatin Pembrolizumab Gemcitabine | Study of Neoadjuvant Pembrolizumab in Combination With Gemcitabine Based Therapy in Cis-eligible or -Ineligible Subjects With Urothelial Cancer | Active, not recruiting | USA | 0 |
| NCT05104866 | Phase III | Gemcitabine Capecitabine Datopotamab Deruxtecan Vinorelbine Eribulin | A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01) | Recruiting | USA | ITA | FRA | ESP | DEU | CAN | BEL | 14 |
| NCT04943627 | Phase III | Topotecan Balstilimab Gemcitabine Irinotecan Pemetrexed Disodium Vinorelbine | Balstilimab in Patients With Recurrent Cervical Cancer. | Terminated | USA | 1 |
| NCT04658862 | Phase III | Cisplatin Cetrelimab + TAR-200 Gemcitabine | A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder | Recruiting | USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT | 20 |
| NCT01956812 | Phase III | Yttrium Y-90 clivatuzumab tetraxetan Gemcitabine | Phase 3 Trial of 90Y-Clivatuzumab Tetraxetan & Gemcitabine vs Placebo & Gemcitabine in Metastatic Pancreatic Cancer (PANCRIT-1) | Terminated | USA | FRA | ESP | CAN | BEL | AUT | 2 |
| NCT03191786 | Phase III | Atezolizumab Gemcitabine Vinorelbine | A Study of Atezolizumab Compared With a Single-Agent Chemotherapy in Treatment Naive Participants With Locally Advanced or Recurrent or Metastatic Non-Small Cell Lung Cancer Who Are Deemed Unsuitable For Platinum-Doublet Chemotherapy (IPSOS) | Active, not recruiting | ITA | ESP | DEU | CAN | BEL | 20 |
| NCT02422381 | Phase Ib/II | Gemcitabine Pembrolizumab | MK-3475 and Gemcitabine in Non-Small Cell Lung Cancer (NSCLC) | Active, not recruiting | USA | 0 |
| NCT02620865 | Phase Ib/II | Paclitaxel Aldesleukin Oxaliplatin Sargramostim Gemcitabine Fluorouracil + Leucovorin | Bispecific Antibody Armed Activated T-cells With Aldesleukin and Sargramostim in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer | Completed | USA | 0 |
| NCT01586611 | Phase III | Gemcitabine Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab | A Study to See if hENT1 Testing on Tumour Tissue Can Predict Response to Treatment With Gemcitabine Chemotherapy and if a Different Chemotherapy Called FOLFOX is Better Than Gemcitabine in Metastatic Pancreas Cancer | Unknown status | CAN | 0 |
| NCT03259503 | Phase Ib/II | Busulfan Olaparib Vorinostat Palifermin Gemcitabine Melphalan Dexamethasone Pyridoxine Rituximab | Olaparib Combined With High-Dose Chemotherapy for Refractory Lymphomas | Recruiting | USA | 0 |
| NCT04241185 | Phase III | Pembrolizumab Cisplatin Mitomycin C Gemcitabine Fluorouracil | Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992) | Recruiting | USA | ITA | FRA | ESP | 20 |
| NCT03056599 | Phase I | Pembrolizumab Avelumab Interferon gamma Olaratumab Trabectedin Nivolumab Gemcitabine Interferon alpha-2b Doxorubicin Atezolizumab Eribulin Ipilimumab Durvalumab Aldesleukin Bortezomib Docetaxel | Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO™ Device in Soft Tissue Sarcoma | Completed | USA | 0 |
| NCT02009449 | Phase I | Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Pembrolizumab Carboplatin Gemcitabine Docetaxel Pazopanib Capecitabine Paclitaxel Cisplatin Pegilodecakin Nab-paclitaxel | A Phase 1 Study of AM0010 in Patients With Advanced Solid Tumors | Active, not recruiting | USA | 0 |
| NCT02142738 | Phase III | Cisplatin Paclitaxel Carboplatin Gemcitabine Pembrolizumab Pemetrexed Disodium | Study of Pembrolizumab (MK-3475) Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (MK-3475-024/KEYNOTE-024) | Completed | 0 | |
| NCT01013649 | Phase II | Erlotinib + Gemcitabine Gemcitabine | Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery | Active, not recruiting | USA | CAN | BEL | 1 |
| NCT02565758 | Phase I | Gemcitabine Nivolumab Nab-paclitaxel ABBV-085 | ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Cancer Tumors | Completed | USA | FRA | ESP | 0 |
| NCT01959672 | Phase II | Nelfinavir Oregovomab Fluorouracil + Leucovorin Gemcitabine | Combination Chemotherapy With or Without Oregovomab Followed by Stereotactic Body Radiation Therapy and Nelfinavir Mesylate in Treating Patients With Locally Advanced Pancreatic Cancer | Completed | USA | 0 |
| NCT02041533 | Phase III | Nivolumab Paclitaxel Cisplatin Pemetrexed Disodium Carboplatin Gemcitabine | An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026) | Completed | USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT | 18 |
| NCT01164228 | Phase II | Sunitinib Gemcitabine | Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery | Completed | USA | 0 |
| NCT02364713 | Phase II | Pegylated liposomal-doxorubicin Bevacizumab + Topotecan Topotecan Paclitaxel MV-NIS Bevacizumab + Paclitaxel Bevacizumab + Pegylated liposomal-doxorubicin Gemcitabine | MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer | Recruiting | USA | 0 |
| NCT04657068 | Phase Ib/II | ART0380 + Gemcitabine ART0380 Gemcitabine | A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors | Recruiting | USA | 1 |
| NCT01935947 | Phase II | Gemcitabine Azacitidine + Entinostat Docetaxel + Irinotecan + Pemetrexed Disodium | Azacitidine and Entinostat Before Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer | Terminated | USA | 0 |
| NCT01438112 | Phase II | Valrubicin Mitomycin C CG0070 Interferon gamma Gemcitabine | Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer (BOND) | Terminated | USA | 0 |
| NCT02788201 | Phase II | Erlotinib Thiotepa Imatinib Dacarbazine Arsenic trioxide Idarubicin Mitomycin C Thioguanine Mercaptopurine Methotrexate Cladribine Epirubicin Gemcitabine Doxorubicin Bleomycin Etoposide Gefitinib Daunorubicin Lomustine Sorafenib Sunitinib Ifosfamide Asparaginase Ixabepilone Abiraterone Azacitidine Ruxolitinib Decitabine Axitinib Estramustine Floxuridine Lapatinib Carmustine Fludarabine Nilotinib Cisplatin Vismodegib Vandetanib Melphalan Busulfan Carboplatin Toremifene Crizotinib Dactinomycin Temsirolimus Vorinostat Romidepsin Fluorouracil Irinotecan Bortezomib Tamoxifen Topotecan Chlorambucil Pentostatin Eribulin Carfilzomib Vemurafenib Hydroxyurea Exemestane Vincristine Sulfate Dasatinib Mitoxantrone Vinblastine Cytarabine Tretinoin Clofarabine Teniposide Docetaxel Pazopanib Oxaliplatin Streptozocin Paclitaxel Bendamustine Mechlorethamine Mitotane | Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma | Completed | USA | 0 |
| NCT01248949 | Phase I | Bevacizumab MEDI3617 Gemcitabine Carboplatin Paclitaxel | A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors | Completed | USA | 0 |
| NCT04172675 | Phase II | Erdafitinib Gemcitabine Mitomycin C | A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) | Recruiting | USA | ITA | FRA | ESP | DEU | BEL | 11 |
| NCT02981342 | Phase II | Capecitabine Abemaciclib Gemcitabine Abemaciclib + LY3023414 Abemaciclib + Galunisertib | A Study of Abemaciclib (LY2835219) Alone or in Combination With Other Agents in Participants With Previously Treated Pancreatic Ductal Adenocarcinoma | Completed | USA | FRA | ESP | BEL | 4 |
| NCT03901339 | Phase III | Eribulin Gemcitabine Vinorelbine Capecitabine Sacituzumab govitecan-hziy | Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast Cancer | Active, not recruiting | USA | ITA | FRA | ESP | DEU | CAN | BEL | 2 |
| NCT05092360 | Phase III | Pembrolizumab ALKS 4230 Topotecan Paclitaxel Pegylated liposomal-doxorubicin Gemcitabine ALKS 4230 + Pembrolizumab | Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab (ARTISTRY-7) | Recruiting | USA | CAN | 0 |
| NCT03498521 | Phase II | Atezolizumab + Paclitaxel Carboplatin Carboplatin + Paclitaxel Olaparib Vismodegib Alectinib Bevacizumab + Erlotinib Cisplatin + Gemcitabine Cobimetinib + Vemurafenib Ipatasertib + Paclitaxel Cisplatin + Paclitaxel Gemcitabine Atezolizumab Entrectinib Pertuzumab + Trastuzumab Paclitaxel + Pertuzumab + Trastuzumab Ipatasertib Carboplatin + Gemcitabine | A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site (CUPISCO) | Recruiting | ITA | FRA | ESP | DEU | AUT | 30 |
| NCT03257267 | Phase III | Irinotecan Gemcitabine Vinorelbine Pemetrexed Disodium Cemiplimab Topotecan | Study of REGN2810 in Adults With Cervical Cancer | Active, not recruiting | USA | ITA | ESP | CAN | BEL | 9 |
| NCT02352948 | Phase III | Durvalumab Vinorelbine Durvalumab + Tremelimumab Gemcitabine Erlotinib Tremelimumab | A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer (ARCTIC) | Active, not recruiting | USA | ITA | FRA | ESP | DEU | CAN | BEL | 19 |
| NCT02477826 | Phase III | Nivolumab Cisplatin Ipilimumab Pemetrexed Disodium Carboplatin Gemcitabine | An Open-Label, Trial of Nivolumab and Nivolumab Plus Ipilimumab Versus Platinum Doublet Chemotherapy in Subjects With Stage IV Non-Small Cell Lung Cancer (NSCLC) | Active, not recruiting | USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT | 25 |
| NCT03456076 | Phase III | Cisplatin Alectinib Carboplatin Gemcitabine Pemetrexed Disodium Vinorelbine | A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer | Active, not recruiting | USA | ITA | FRA | ESP | DEU | AUT | 21 |
| NCT02101775 | Phase II | Gemcitabine Adavosertib + Gemcitabine | Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | Active, not recruiting | USA | CAN | 1 |
| NCT02492711 | Phase III | Vinorelbine Capecitabine Gemcitabine Trastuzumab Eribulin Margetuximab-cmkb | Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer | Active, not recruiting | USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT | 10 |
| NCT03512756 | Phase II | Methoxsalen + Phenytoin + Sirolimus + SM88 Gemcitabine Fluorouracil Capecitabine | A Multi-Center Study of SM-88 in Subjects With Pancreatic Cancer | Completed | USA | 0 |
| NCT02331251 | Phase Ib/II | Vinorelbine Pembrolizumab Irinotecan Doxorubicin Gemcitabine Docetaxel Nab-paclitaxel | Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus) | Terminated | USA | 0 |
| NCT02701673 | Phase Ib/II | Azacitidine Pyridoxine Gemcitabine Belinostat Busulfan Melphalan | Belinostat Combined With Azacitidine/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Refractory or Relapsed Lymphoma | Withdrawn | 0 | |
| NCT04807816 | Phase II | Berzosertib + Gemcitabine Gemcitabine | Targeting ATR in Soft-tissue Sarcomas (TARSARC) | Recruiting | FRA | 0 |
| NCT01879085 | Phase Ib/II | Gemcitabine Docetaxel Pegfilgrastim Vorinostat | Phase 1b/2 Study of Vorinostat in Combination With Gemcitabine and Docetaxel in Advanced Sarcoma | Completed | USA | 0 |
| NCT03126435 | Phase III | EndoTAG-1 + Gemcitabine Gemcitabine | EndoTAG-1 Plus Gemcitabine Versus Gemcitabine Alone in Patients With Measurable Locally Advanced and/or Metastatic Adenocarcinoma of the Pancreas Failed on FOLFIRINOX Treatment | Completed | USA | FRA | 5 |
| NCT01945775 | Phase III | Gemcitabine Capecitabine Vinorelbine Talazoparib Eribulin | A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study) (EMBRACA) | Completed | USA | ITA | FRA | ESP | DEU | BEL | 10 |
| NCT02555657 | Phase III | Pembrolizumab Eribulin Gemcitabine Vinorelbine Capecitabine | Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119) | Completed | 0 | |
| NCT03697564 | FDA approved | Cabiralizumab + Gemcitabine + Nivolumab Gemcitabine | Nivolumab + Cabiralizumab + Gemcitabine Versus Gemcitabine in Patients With Stage IV Pancreatic Cancer Achieving Disease Control in Response to First-line Chemotherapy (GemCaN Trial). | Suspended | USA | 0 |
| NCT01858883 | Phase I | Nab-paclitaxel Filgrastim Itacitinib Gemcitabine | Safety Study of INCB039110 in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors | Completed | USA | 0 |
| NCT01454102 | Phase I | Bevacizumab Ipilimumab Cisplatin Pemetrexed Disodium Gemcitabine Erlotinib Carboplatin Paclitaxel Nivolumab | Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012) | Completed | USA | CAN | 0 |
| NCT04679064 | Phase III | Bevacizumab + Gemcitabine Dostarlimab-gxly + Niraparib Pegylated liposomal-doxorubicin Bevacizumab + Topotecan Paclitaxel Topotecan Bevacizumab + Paclitaxel Bevacizumab + Pegylated liposomal-doxorubicin Gemcitabine | Trial on NIraparib-TSR-042 (Dostarlimab) vs Physician's Choice CHEmotherapy in Recurrent, Ovarian, Fallopian Tube or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment (NItCHE-MITO33) | Recruiting | ITA | 0 |
| NCT02322281 | Phase III | Pemetrexed Disodium Gemcitabine Paclitaxel Docetaxel Rociletinib | TIGER-3 Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy | Terminated | USA | ITA | FRA | ESP | DEU | 5 |
| NCT03057106 | Phase II | Cisplatin Gemcitabine Carboplatin Durvalumab + Tremelimumab Pemetrexed Disodium | Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC | Active, not recruiting | CAN | 1 |
| NCT04216290 | Phase II | Cisplatin + Doxorubicin + Methotrexate + Vinblastine Durvalumab + Fluorouracil + Mitomycin C Gemcitabine Fluorouracil + Mitomycin C Durvalumab + Gemcitabine Cisplatin + Durvalumab Cisplatin + Gemcitabine Carboplatin + Gemcitabine Cisplatin Durvalumab | A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, the INSPIRE Study | Recruiting | USA | 0 |
| NCT02855944 | Phase III | Cisplatin Rucaparib Carboplatin Gemcitabine Paclitaxel | ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients | Active, not recruiting | USA | ITA | ESP | CAN | 8 |
| NCT04310007 | Phase II | Nab-paclitaxel Gemcitabine Cabozantinib + Nivolumab Cabozantinib Docetaxel Paclitaxel Docetaxel + Ramucirumab | Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer | Recruiting | USA | 0 |
| NCT02312245 | Phase II | Topotecan Doxorubicin Paclitaxel Gemcitabine | Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | Recruiting | USA | 0 |
| NCT01610206 | Phase II | Gemcitabine + Pazopanib Gemcitabine | A Randomized Study of Safety and Efficacy of Pazopanib and Gemcitabine in Persistent or Relapsed Ovarian Cancer | Completed | USA | 0 |
| NCT02506959 | Phase II | Dexamethasone Busulfan + Melphalan Pyridoxine Panobinostat Palifermin Gemcitabine | Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Myeloma | Active, not recruiting | USA | 0 |
| NCT02437370 | Phase I | Pembrolizumab Gemcitabine Docetaxel | Pembrolizumab and Docetaxel or Gemcitabine Hydrochloride in Treating Patients Urothelial Cancer | Active, not recruiting | USA | 0 |
| NCT02631876 | Phase II | Paclitaxel + Pegylated liposomal-doxorubicin Gemcitabine Topotecan Mirvetuximab Soravtansine | PH2 Study of IMGN853 vs Investigator's Choice of Chemo in Adults With FRa+ Adv. EOC, Primary Peritoneal or Primary Fallopian Tube Cancer | Completed | USA | ITA | FRA | ESP | CAN | BEL | 7 |
| NCT04697628 | Phase III | Topotecan Gemcitabine Irinotecan Tisotumab vedotin-tftv Pemetrexed Disodium Vinorelbine | Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer (innovaTV 301) | Recruiting | USA | ITA | FRA | ESP | CAN | BEL | 14 |
| NCT03819465 | Phase I | Gemcitabine Durvalumab + Oleclumab Carboplatin Pemetrexed Disodium Nab-paclitaxel AZD9150 + Durvalumab Cisplatin Durvalumab | A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC (MAGELLAN) | Active, not recruiting | USA | ESP | CAN | BEL | AUT | 5 |
| NCT00565851 | Phase III | Gemcitabine Docetaxel + Paclitaxel Carboplatin Bevacizumab | Carboplatin, Paclitaxel and Gemcitabine With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer | Active, not recruiting | USA | 2 |
CKB BOOST